Main clinical and laboratory data of 35 healthy subjects (HS) and 167 HCV-chronically infected patients with mixed cryoglobulinemia (MC-HCV) or HCV-related non-Hodgkin’s lymphoma (NHL-HCV) or without MC or NHL (HCV).

<p>Results are presented as mean± standard deviation;</p><p>ns, not significant;</p>∧<p>ALT, alanine aminotransferase;</p><p>ULN, upper limit of normal.</p>#<p>Complement C3, normal values: 83 to 177 mg/dL;</p>‡<p>Complement C4, normal values: 20 to 150 mg/dL;</p>†<p>Rheumatoid Factor, normal values: <25 IU/mL.</p>*<p>HS vs MC-HCV; HS vs NHL-HCV; HCV vs MC-HCV.</p>**<p>HS vs MC-HCV; HS vs NHL-HCV; HCV vs MC-HCV; HCV vs NHL-HCV.</p>***<p>HCV vs MC-HCV.</p><p>°HS or HCV vs MC-HCV or NHL-HCV.</p

Principal mixed cryoglobulinemia (MC) manifestations present in the 75 HCV patients with MC (MC-HCV).

<p>Principal mixed cryoglobulinemia (MC) manifestations present in the 75 HCV patients with MC (MC-HCV).</p

Identification of a reference miRNA (internal control) for relative quantification of miRNA of interest: expression levels of Let-7d (panel A) and miR-16 (panel B) in HCV patients and controls.

<p>Identification of a reference miRNA (internal control) for relative quantification of miRNA of interest: expression levels of Let-7d (panel A) and miR-16 (panel B) in HCV patients and controls.</p

Expression levels of miR-26b in HS, HBV, HCV, MC-HCV and NHL-HCV groups and in a subgroup of MC-HCV patients after therapy-induced clearance of the viral infection and complete clinical response (MC post Tp).

<p>Expression levels of miR-26b in HS, HBV, HCV, MC-HCV and NHL-HCV groups and in a subgroup of MC-HCV patients after therapy-induced clearance of the viral infection and complete clinical response (MC post Tp).</p

Drug classes used as comedication when beginning DAA therapy, by severity of liver disease, among HCV-infected patients.

<p>Drug classes used as comedication when beginning DAA therapy, by severity of liver disease, among HCV-infected patients.</p

Sociodemographic and virological characteristics and comedications used, by severity of liver disease, among HCV-infected patients undergoing DAA therapy.

<p>Sociodemographic and virological characteristics and comedications used, by severity of liver disease, among HCV-infected patients undergoing DAA therapy.</p

Number of co-medications used and percentage of patients, by DAA regimen, among HCV-infected patients.

<p>(A) Patients with mild liver disease. (B) Patients with moderate-to severe-liver disease. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. The percentage of patients who took one drug (in blu), two drugs (in red), three drugs (in green) and more than 3 drugs (in violet) are reported considering the total number of patients reported for each regimen in both Fig 1A and Fig 1B at the same manner.</p

Category of potential DDIs, by DAA regimen and severity of liver disease, among HCV-infected patients.

<p>Comedication used in patients with mild liver disease (A) or in (B) patients with moderate-to severe-liver disease (B). DAA regiments and number of comedications used are shown. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. Category 0: Classification not possible due to lack of information; Category 1: No clinical interaction possible; Category 2: May require dose adjustment/closer monitoring.</p

The most common drugs with a potential DDI among HCV-infected patients with moderate-to-severe liver disease.

<p>The most common drugs with a potential DDI among HCV-infected patients with moderate-to-severe liver disease.</p

Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).

<p>Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).</p